Search

Kevin M Gardinier

from Arlington, MA
Age ~50
Get Report
Also known as:
Kevin Matthew Gardinier, Kevin Gardinier, Kevin Gardiner
Related to:
Mariajesus Pillado, 51Barbara G Gardinier, 74Angela L Logan, 50Harvey A Gardinier, 77Harvey A Gardinier, 52Maria J Blanco PilladoTracy L Gardinier, 44
Connected to:
Andrea D Gardinier, 50Brian J Gardinier, 52Charles E Gardinier, 45Chris Gardinier, 36Leslee L Gardinier, 69Lisa M Gardinier, 69Steve D Gardinier, 53Thomas A Gardinier, 61Raymond M Gardino, 63Arlene C Gardipee, 87

Kevin Gardinier Phones & Addresses

  • Arlington, MA
  • 11874 Gray Eagle Dr, Fishers, IN 46037 (317) 915-8235
  • 7278 Hawthorne Rd, Indianapolis, IN 46250 (317) 915-8235
  • Schaumburg, IL
  • Berkeley, CA
  • Georgetown, NY
  • Palo Alto, CA

Work

Company: Eli lilly Oct 2007 to 2012 Position: Group leader - discovery chemistry research & technologies (neuroscience)

Education

Degree: Post-Doc School / High School: Université Louis Pasteur (Strasbourg I) 1998 to 2000 Specialities: Syntheic Chemistry, Molecular Recognition

Skills

Neuroscience • Drug Discovery

Awards

Chateaubriand Postdoctoral Fellowship -1... • NSF-NATO Postdoctoral Fellowship- 1998 • Squibb Graduate Research Fellowship- 1998 • ACS, Division of Organic Chemistry Gradu...

Industries

Pharmaceuticals

Resumes

Resumes

Kevin Gardinier Photo 1

Research Advisor

View page
Position:
Group Leader - Discovery Chemistry Research & Technologies (Neuroscience) at Eli Lilly
Location:
Indianapolis, Indiana Area
Industry:
Pharmaceuticals
Work:
Eli Lilly since Oct 2007
Group Leader - Discovery Chemistry Research & Technologies (Neuroscience)
Eli Lilly Oct 2004 - Oct 2007
Senior Research Scientist
Eli Lilly Jan 2003 - Oct 2004
Research Scientist
Eli Lilly Feb 2000 - Jan 2003
Senior Organic Chemist
UC Berkeley 1994 - 1998
Graduate Student
Education:
Université Louis Pasteur (Strasbourg I) 1998 - 2000
Post-Doc, Syntheic Chemistry, Molecular Recognition University of California, Berkeley 1994 - 1998
Ph.D., Organic Synthesis, Natural Products Colgate University
Skills:
Neuroscience
Drug Discovery
Honor & Awards:
Chateaubriand Postdoctoral Fellowship -1999 NSF-NATO Postdoctoral Fellowship- 1998 Squibb Graduate Research Fellowship- 1998 ACS, Division of Organic Chemistry Graduate Fellowship- 1997

Publications

Us Patents

Cb1 Antagonist Compounds

View page
US Patent:
7276516, Oct 2, 2007
Filed:
Dec 13, 2004
Appl. No.:
10/596495
Inventors:
Jennifer Rebecca Allen - Indianapolis IN,
Albert Kudzovi Amegadzie - Indianapolis IN,
Kevin Matthew Gardinier - Indianapolis IN,
George Stuart Gregory - Fishers IN,
Steven Andrew Hitchcock - Westlake Village CA,
Paul J. Hoogestraat - Indianapolis IN,
Daryl Lynn Smith - Fishers IN,
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A01N 43/42
A01N 43/38
A61K 31/44
C07D 471/02
C07D 491/02
US Classification:
514300, 514414, 514418, 514404, 546113, 5462771, 548469, 5483611
Abstract:
Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e. g. , multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

Triazole Derivatives As Tachykinin Receptor Antagonists

View page
US Patent:
7320994, Jan 22, 2008
Filed:
Apr 22, 2003
Appl. No.:
10/512249
Inventors:
Albert Kudzovi Amegadzie - Indianapolis IN,
Kevin Matthew Gardinier - Indianapolis IN,
Erik James Hembre - Indianapolis IN,
Jian Eric Hong - Carmel IN,
Louis Nickolaus Jungheim - Indianapolis IN,
Brian Stephen Muehl - Greenwood IN,
David Michael Remick - Fishers IN,
Michael Alan Robertson - Indianapolis IN,
Kenneth Allen Savin - Indianapolis IN,
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31/41
C07D 249/04
US Classification:
514359, 548255
Abstract:
This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C-Calkane-diyl; Ris phenyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C-Calkyl, C-Calkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; Ris a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH).

Retinoid X Receptor Modulators

View page
US Patent:
7348359, Mar 25, 2008
Filed:
Mar 14, 2002
Appl. No.:
10/471330
Inventors:
Kevin M. Gardinier - Indianapolis IN,
Douglas L. Gernert - Indianapolis IN,
Timothy A. Grese - Indianapolis IN,
David A. Neel - Zionsville IN,
Christopher M. Mapes - San Diego CA,
Pierre-Yves Michellys - San Diego CA,
Marcus F. Boehm - San Diego CA,
Assignee:
Eli Lilly and Company - Indianapolis IN
Ligand Pharmaceuticals - San Diego CA
International Classification:
A61K 31/43
C07D 307/80
C07D 307/81
US Classification:
514469, 549471
Abstract:
The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

Cb1 Modulator Compounds

View page
US Patent:
7595339, Sep 29, 2009
Filed:
Aug 17, 2007
Appl. No.:
11/840417
Inventors:
Jennifer Rebecca Allen - Indianapolis IN,
Albert Kudzovi Amegadzie - Indianapolis IN,
Kevin Matthew Gardinier - Indianapolis IN,
George Stuart Gregory - Fishers IN,
Stephen Andrew Hitchcock - Westlake Village CA,
Paul J. Hoogestraat - Indianapolis IN,
Daryl Lynn Smith - Fishers IN,
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31/40
US Classification:
514418
Abstract:
Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e. g. , multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

Mch Receptor Antagonists

View page
US Patent:
7838543, Nov 23, 2010
Filed:
Dec 16, 2005
Appl. No.:
11/719576
Inventors:
James Peter Beck - Indianapolis IN,
Brian David Wakefield - Skokie IL,
Frederic Laurent Cordier - Alcobendas,
Esteban Dominguez-Manzanares - Alcobendas,
Kevin Matthew Gardinier - Fishers IN,
Peter Michael Greenen - Indianapolis IN,
Kenneth Allen Savin - Indianapolis IN,
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A01N 43/78
A61K 31/425
C07D 417/00
C07D 277/60
US Classification:
514367, 548162, 548152
Abstract:
The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar, L, R, q, X, R, R, R, and Rare as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

Thiazolopyridinone Derivates As Mch Receptor Antagonists

View page
US Patent:
7902356, Mar 8, 2011
Filed:
Dec 16, 2005
Appl. No.:
11/721079
Inventors:
Albert Kudzovi Amegadzie - Indianapolis IN,
James Peter Beck - Zionsville IN,
Kevin Matthew Gardinier - Fishers IN,
Erik James Hembre - Indianapolis IN,
James Craig Ruble - Greenwood IN,
Kenneth Allen Savin - Indianapolis IN,
Brian David Wakefield - Skokie IL,
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07D 265/36
C07D 413/00
C07D 401/00
C07D 513/02
US Classification:
544105, 544128, 544362, 546114
Abstract:
The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R, q, p, R, t, Ar, L, Rand Rare as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

5- [4-(Azetidin-3-Yloxy)-Phenyl]-2-Phenyl-5H-Thiazolo[5,4-C] Pyridin-4-One Derivatives And Their Use As Mch Receptor Antagonists

View page
US Patent:
8049013, Nov 1, 2011
Filed:
Nov 15, 2007
Appl. No.:
12/515432
Inventors:
Kevin Matthew Gardinier - Fishers IN,
David Joseph Garmene - Indianapolis IN,
Erik James Hembre - Indianapolis IN,
Michael Brunavs - Basingstoke,
Helen Jane Szekeres - Basingstoke,
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07D 513/02
US Classification:
546114
Abstract:
The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein “-----” is absent or is optionally a bond; q is 1 or 2; Ris independently selected from hydrogen, —C-Calkyl, halo, hydroxy, —C-Chaloalkyl, —C-Calkoxy, cyano, —O—C-Ccycloalkyl, and —OC-Chaloalkyl; Ris selected from the group consisting of hydrogen, —C-Calkyl, hydroxy, —C-Calkoxy, cyano, —C-Chaloalkyl, —OC-Chaloalkyl, and halo; Ris selected from the group consisting of hydrogen, —C-Calkyl, —C-Chaloalkyl, —C-CalkylOH, —C-Ccycloalkyl, —CHC-Ccycloalkyl, —C-Calkyl-O—C-Calkyl, —C(O)C-Calkyl, —C(O)C-Chaloalkyl, —CH-thiazole, phenyl, benzyl, tetrahydrothiopyranyl, and tetrahydropyranyl, wherein the cycloalkyl, tetrahydrothiopyranyl, tetrahydropyranyl and thiazolyl group is optionally substituted with one or two groups independently selected from the group consisting of halo, hydroxy, C-Calkyl, and —C-Chaloalkyl; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof, useful in the treating, preventing or ameliorating of symptoms associated with obesity and related diseases.

Mch Receptor Antagonists

View page
US Patent:
8101764, Jan 24, 2012
Filed:
Jun 8, 2007
Appl. No.:
12/296557
Inventors:
Albert Kudzovi Amegadzie - Moorpark CA,
Yen Dao - Indianapolis IN,
Kevin Matthew Gardinier - Fishers IN,
David Joseph Garmene - Indianapolis IN,
Steven James Green - Indianapolis IN,
Erik James Hembre - Indianapolis IN,
Jianliang Lu - Fishers IN,
Patrick Gianpietro Spinazze - Fishers IN,
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07D 513/02
US Classification:
546114
Abstract:
The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R, R, R, R, L, R, Rand Rare as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.
Control profile
Kevin M Gardinier from Arlington, MA, age ~50 Get Report